You just read:

Biohaven Secures Priority Review Voucher (PRV) To Expedite Regulatory Review Of Rimegepant Zydis ODT New Drug Application

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Mar 18, 2019, 07:30 ET